Global Fund grants to Thailand aim to strengthen services for key populations and support a successful transition
On 1 December 2017, acting on the recommendation of the Global Fund’s Grant Approvals Committee (GAC), the Board approved two grants emanating from Thailand’s 2017 Window 2 TB/HIV funding request. The Ministry of Health’s Department of Disease Control will serve as principal recipient (PR) for one grant, totaling $18.0 million.
Global Fund Board approves fifth batch of country grants from 2017-2019 allocations, in the amount of $1.22 billion
On 12 January 2018, the Global Fund Board approved 33 country grants worth $1.22 billion. This was the fifth batch of approvals from the 2017–2019 allocations, and brings the cumulative amount awarded to date to $8.86 billion.
TRP praises Kenya's TB/HIV funding request to the Global Fund for its sensitivity to key populations and human rights
On 13 December 2017, the Global Fund Board approved grants worth $1.38 billion from the 2017-2019 allocations. This was the fourth batch of approvals from the 2017–2019 allocations, and brings the cumulative amount awarded to date to $7.64 billion.
Nigeria’s grant portfolio continues to provide plenty of drama.
On 1 December 2017, the Global Fund Board approved grants worth $2.83 billion from the 2017-2019 allocations. This is the largest amount approved in a single batch since the start of the new funding model.
Global Fund makes significant progress on Strategy implementation during a busy year of grant-making
A report prepared for the Board meeting on 14-15 November in Geneva, Switzerland provided an update on the implementation of activities under the objectives and sub-objectives of the Global Fund’s 2017-2022 Strategy. For each sub-objective, the report described the progress achieved to date, as well as key challenges and risks, and future plans. In addition, the report identified the key performance indicator (KPI) tied to each sub-objective.
In line with the Global Fund’s eligibility policy, Cuba is no longer eligible for regular Global Fund financing, and so it had submitted a funding request tailored to transition for its HIV component.